VIENNA (MedPage Today) -- An investigational androgen receptor antagonist achieved partial response or stable disease after 12 weeks of therapy in almost all evaluable patients with castration-resistant prostate cancer, an initial clinical study showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment